Lipid abnormalities and renal disease

Is dyslipidemia a predictor of progression of renal disease?

Errol D. Crook, Anantha Thallapureddy, Stephen Migdal, John M. Flack, Eddie L. Greene, Abdullah Salahudeen, John K. Tucker, Herman A. Taylor

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Dyslipidemia is a cardiovascular disease (CVD) risk factor that is associated with enhanced atherosclerosis and plaque instability. Renal insufficiency is associated with abnormalities in lipoprotein metabolism in both the early and the advanced stages of chronic renal failure. These include alterations in apolipoprotein A (apo A)- and B- containing lipoproteins, high-density lipoproteins, and triglycerides. In animal models, these alterations in lipid metabolism and action lead to macrophage activation and infiltration in the kidney with resultant tubulointerstitial and endothelial cell injury. Limited data in humans suggest that, in addition to contributing to CVD, dyslipidemia may be a risk factor for the progression of renal disease. The effects of dyslipidemia on the kidney are mainly observed in those with other risk factors for renal disease progression such as hypertension, diabetes, and proteinuria. Renal disease is a strong risk factor for CVD and African Americans have high rates of renal disease. Therefore, examining the effects of dyslipidemia on the development or progression or renal disease will be an important question for the Jackson Heart Study and is the topic of this review.

Original languageEnglish (US)
Pages (from-to)340-348
Number of pages9
JournalAmerican Journal of the Medical Sciences
Volume325
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Dyslipidemias
Disease Progression
Kidney
Lipids
Cardiovascular Diseases
Lipoproteins
Apolipoproteins A
Macrophage Activation
Apolipoproteins B
HDL Lipoproteins
Proteinuria
Lipid Metabolism
African Americans
Chronic Kidney Failure
Renal Insufficiency
Atherosclerosis
Endothelial Cells
Animal Models
Hypertension
Wounds and Injuries

Keywords

  • Chronic kidney disease
  • Dyslipidemia
  • HDL cholesterol
  • Jackson Heart Study
  • LDL cholesterol
  • Triglycerides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Crook, E. D., Thallapureddy, A., Migdal, S., Flack, J. M., Greene, E. L., Salahudeen, A., ... Taylor, H. A. (2003). Lipid abnormalities and renal disease: Is dyslipidemia a predictor of progression of renal disease? American Journal of the Medical Sciences, 325(6), 340-348. https://doi.org/10.1097/00000441-200306000-00005

Lipid abnormalities and renal disease : Is dyslipidemia a predictor of progression of renal disease? / Crook, Errol D.; Thallapureddy, Anantha; Migdal, Stephen; Flack, John M.; Greene, Eddie L.; Salahudeen, Abdullah; Tucker, John K.; Taylor, Herman A.

In: American Journal of the Medical Sciences, Vol. 325, No. 6, 01.06.2003, p. 340-348.

Research output: Contribution to journalArticle

Crook, ED, Thallapureddy, A, Migdal, S, Flack, JM, Greene, EL, Salahudeen, A, Tucker, JK & Taylor, HA 2003, 'Lipid abnormalities and renal disease: Is dyslipidemia a predictor of progression of renal disease?', American Journal of the Medical Sciences, vol. 325, no. 6, pp. 340-348. https://doi.org/10.1097/00000441-200306000-00005
Crook, Errol D. ; Thallapureddy, Anantha ; Migdal, Stephen ; Flack, John M. ; Greene, Eddie L. ; Salahudeen, Abdullah ; Tucker, John K. ; Taylor, Herman A. / Lipid abnormalities and renal disease : Is dyslipidemia a predictor of progression of renal disease?. In: American Journal of the Medical Sciences. 2003 ; Vol. 325, No. 6. pp. 340-348.
@article{7deb3074348c423697b8dcf322048964,
title = "Lipid abnormalities and renal disease: Is dyslipidemia a predictor of progression of renal disease?",
abstract = "Dyslipidemia is a cardiovascular disease (CVD) risk factor that is associated with enhanced atherosclerosis and plaque instability. Renal insufficiency is associated with abnormalities in lipoprotein metabolism in both the early and the advanced stages of chronic renal failure. These include alterations in apolipoprotein A (apo A)- and B- containing lipoproteins, high-density lipoproteins, and triglycerides. In animal models, these alterations in lipid metabolism and action lead to macrophage activation and infiltration in the kidney with resultant tubulointerstitial and endothelial cell injury. Limited data in humans suggest that, in addition to contributing to CVD, dyslipidemia may be a risk factor for the progression of renal disease. The effects of dyslipidemia on the kidney are mainly observed in those with other risk factors for renal disease progression such as hypertension, diabetes, and proteinuria. Renal disease is a strong risk factor for CVD and African Americans have high rates of renal disease. Therefore, examining the effects of dyslipidemia on the development or progression or renal disease will be an important question for the Jackson Heart Study and is the topic of this review.",
keywords = "Chronic kidney disease, Dyslipidemia, HDL cholesterol, Jackson Heart Study, LDL cholesterol, Triglycerides",
author = "Crook, {Errol D.} and Anantha Thallapureddy and Stephen Migdal and Flack, {John M.} and Greene, {Eddie L.} and Abdullah Salahudeen and Tucker, {John K.} and Taylor, {Herman A.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1097/00000441-200306000-00005",
language = "English (US)",
volume = "325",
pages = "340--348",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Lipid abnormalities and renal disease

T2 - Is dyslipidemia a predictor of progression of renal disease?

AU - Crook, Errol D.

AU - Thallapureddy, Anantha

AU - Migdal, Stephen

AU - Flack, John M.

AU - Greene, Eddie L.

AU - Salahudeen, Abdullah

AU - Tucker, John K.

AU - Taylor, Herman A.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Dyslipidemia is a cardiovascular disease (CVD) risk factor that is associated with enhanced atherosclerosis and plaque instability. Renal insufficiency is associated with abnormalities in lipoprotein metabolism in both the early and the advanced stages of chronic renal failure. These include alterations in apolipoprotein A (apo A)- and B- containing lipoproteins, high-density lipoproteins, and triglycerides. In animal models, these alterations in lipid metabolism and action lead to macrophage activation and infiltration in the kidney with resultant tubulointerstitial and endothelial cell injury. Limited data in humans suggest that, in addition to contributing to CVD, dyslipidemia may be a risk factor for the progression of renal disease. The effects of dyslipidemia on the kidney are mainly observed in those with other risk factors for renal disease progression such as hypertension, diabetes, and proteinuria. Renal disease is a strong risk factor for CVD and African Americans have high rates of renal disease. Therefore, examining the effects of dyslipidemia on the development or progression or renal disease will be an important question for the Jackson Heart Study and is the topic of this review.

AB - Dyslipidemia is a cardiovascular disease (CVD) risk factor that is associated with enhanced atherosclerosis and plaque instability. Renal insufficiency is associated with abnormalities in lipoprotein metabolism in both the early and the advanced stages of chronic renal failure. These include alterations in apolipoprotein A (apo A)- and B- containing lipoproteins, high-density lipoproteins, and triglycerides. In animal models, these alterations in lipid metabolism and action lead to macrophage activation and infiltration in the kidney with resultant tubulointerstitial and endothelial cell injury. Limited data in humans suggest that, in addition to contributing to CVD, dyslipidemia may be a risk factor for the progression of renal disease. The effects of dyslipidemia on the kidney are mainly observed in those with other risk factors for renal disease progression such as hypertension, diabetes, and proteinuria. Renal disease is a strong risk factor for CVD and African Americans have high rates of renal disease. Therefore, examining the effects of dyslipidemia on the development or progression or renal disease will be an important question for the Jackson Heart Study and is the topic of this review.

KW - Chronic kidney disease

KW - Dyslipidemia

KW - HDL cholesterol

KW - Jackson Heart Study

KW - LDL cholesterol

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=0038517698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038517698&partnerID=8YFLogxK

U2 - 10.1097/00000441-200306000-00005

DO - 10.1097/00000441-200306000-00005

M3 - Article

VL - 325

SP - 340

EP - 348

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 6

ER -